Increased red cell destruction (hemolysis)

January 29, 2018 | Author: Anonymous | Category: Science, Health Science, Immunology
Share Embed Donate


Short Description

Download Increased red cell destruction (hemolysis)...

Description

ANEMIA Classified by cause 1.

Decreased red cell production a. Stem cell damage - neutrophils, platelets often affected also b. Defective red cell maturation

2.

Increased red cell destruction (hemolysis) a. Intrinsic defect in red cell leading to shortened lifespan b. External factors in blood or blood vessels destroy red cells

3.

Blood loss

HEMOLYTIC ANEMIA  Increased rate of red cell destruction  Increased rate of production - increased reticulocytes  Red cell destruction causes increased bilirubin production and jaundice

 Most red cell destruction occurs in spleen • splenectomy may cause improvement

Hemolytic anemia: low hematocrit, plasma too yellow due to high bilirubin

INHERITED HEMOLYTIC ANEMIA Sickle cell anemia  Mutation changes structure of hemoglobin  Mutant hemoglobin (deoxy form) polymerizes in cells and damages cell membranes • membrane damage causes hemolysis • hemoglobin crystals change cell shape to "sickle" • sickled cells are rigid and block small blood vessels, causing tissue damage O 2

“Sickled” cell

 Genetics: mainly affects those of African and Middle Eastern descent; recessive inheritance (carriers partially protected from malaria)

SICKLE CELL ANEMIA

Sickle cell

Normal

Sickle Cell

Normal red cell

Sickle cells inflexible, can’t do this

Sickle cell anemia - pathophysiology

Retinal vessel occlusion in sickle disease

IMMUNE HEMOLYTIC ANEMIA  Production of "autoantibodies" against one's own red cells  Antibodies coat cells and lead to destruction in spleen and liver  Positive Coombs test (detects antibodies on red cells) in most cases  Treatment: corticosteroids, splenectomy, i.v. gamma globulin

TRANSFUSION REACTION  Giving a person blood of the wrong type may cause destruction of the transfused cells (hemolysis) by antibodies in the recipient's blood  The most serious reactions occur with blood mismatched for antigens in the ABO system: • giving O patient A, B, or AB blood • giving A patient B or AB blood • giving B patient A or AB blood  In such instances there may be very rapid hemolysis accompanied by shock, kidney failure, bleeding, and death

HEMOLYTIC DISEASE OF THE NEWBORN  Caused by maternal antibodies against antigens on fetal red cells (usually Rh antigens); mother usually exposed (sensitized) to Rh antigen during prior pregnancy  These antibodies cross the placenta and cause destruction of fetal red cells  Infant liver unable to properly metabolize hemoglobin breakdown products (bilirubin)  Stillbirth or anemia, jaundice, and brain damage may result  Prevention: prevent sensitization by giving antibody against Rh factor (Rhogam) to Rh-negative woman soon after delivery of Rh-positive child

POLYCYTHEMIA  Definition: increased total red cell volume • high hematocrit • thick blood can cause thrombosis, other circulatory disorders  Polycythemia vera: increased, unregulated red cell production • Most cases due to an acquired mutation in marrow cells that makes red cell precursors much more sensitive to erythropoietin  Secondary polycythemia: increased erythropoietin production due to decreased oxygen delivery to kidney • Often due to low levels of oxygen in the blood

NEUTROPHIL DISORDERS  Neutropenia (decreased neutrophils) • Decreased production (bone marrow failure, cancer chemotherapy) • Increased consumption (some infections, enlarged spleen, autoimmune)  Increased risk of infection when neutrophil count low  Neutrophilia (increased neutrophils) • Increased production due to physiologic stimuli (e.g., infection) • Increased production due to bone marrow neoplasm

10/31/97

neutrophils 0

11/7/97

neutrophils 19,000

2/12/98

neutrophils 1200

CANCERS OF THE BLOOD AND LYMPHATIC SYSTEMS

LEUKEMIA  Malignant proliferation of white cells and/or their precursors (blasts)  Myelogenous (neutrophil precursors) • Acute myelogenous leukemia (AML) • Chronic myelogenous leukemia (CML)  Lymphocytic • Acute lymphocytic leukemia (ALL) • Chronic lymphocytic leukemia (CLL)  Chronic leukemias: more mature cells, slow-growing  Acute leukemias: immature cells (blasts), fastgrowing

PATHOPHYSIOLOGY OF LEUKEMIA  Bone marrow failure (marrow fills with leukemic cells) • anemia • neutropenia (infections) • thrombocytopenia (bleeding)  Leukemic cells in blood may impair circulation  Leukemic cells in other organs • spleen, lymph nodes • skin • brain  Toxic substances from leukemic cells • uric acid (gout, kidney failure) • proteolytic enzymes (tissue damage, bleeding)

White cells

Leukemia

GUM INFILTRATION IN ACUTE LEUKEMIA

SKIN INFILTRATION IN ACUTE LEUKEMIA

CEREBRAL HEMORRHAGE IN ACUTE LEUKEMIA

PURPURA IN LEUKEMIA

DISSEMINATED FUNGAL INFECTION IN ACUTE LEUKEMIA

ACUTE LEUKEMIAS  Acute myelogenous leukemia (AML) • adults > children • fatal if untreated • remission, occasional cure possible with intensive chemotherapy • sometimes curable with bone marrow transplant  Acute lymphocytic leukemia (ALL) • children and adults (most common childhood leukemia) • fatal if untreated • curable with chemotherapy or bone marrow transplantation • Cure rates in children > 75%

DIFFERENTIATION OF NEUTROPHILS AND RED CELLS

Cells capable of division

Cells cannot divide

Bone marrow in acute leukemia

Normal

AML

Immature cells (blasts) in acute myelogenous leukemia

Mature lymphocytes in chronic lymphocytic leukemia

CHRONIC LEUKEMIAS  Chronic myelogenous leukemia (CML) • rare in children • treatable but often fatal within 5-10 years  Newer treatments will probably improve the prognosis

• may be curable with bone marrow transplantation  Chronic lymphocytic leukemia (CLL) • almost all patients middle-aged and older • treatable but incurable • not all patients need treatment, many live > 10 years

Enlarged lymph nodes (lymphadenopathy) in chronic lymphocytic leukemia

LYMPHOMAS  Cancer of lymphocytes or their precursors  Forms tumors in lymph nodes, spleen, bone marrow, other organs • Sometimes in blood - overlap with lymphoid leukemia  Many different kinds - spectrum of severity • Hodgkin's vs non-Hodgkin's • B-cell vs T-cell • Mature vs immature lymphoid cells • Fast vs slow-growing  Usually treatable, sometimes curable (chemotherapy, radiation, marrow transplantation)

NON-HODGKIN'S LYMPHOMAS Many types, complex classification scheme  LOW GRADE • Cells appear mature • Good news: slow-growing - patients may live many years with disease • Bad news: treatable but generally incurable • Usually affect older people  HIGH GRADE • Cells less mature • The most aggressive forms resemble acute lymphoblastic leukemia

• Good news: often curable with chemotherapy • Bad news: faster-growing, fatal in months if not treated or treatment doesn't work • Some varieties occur in children • Example: Burkitt lymphoma (resembles acute leukemia)

 Rule of thumb: the less mature the cancer cell, the faster growing the lymphoma, and the more likely the disease is to affect younger people and to be curable

HODGKIN'S DISEASE  Probably a cancer of lymphocytes (lymphoma)  Almost always begins in lymph nodes  Spreads gradually to other lymph nodes & organs stage = extent of spread  Relatively common in young adults  Curable in many cases with radiation or chemotherapy

“Reed-Sternberg” cell characteristic of Hodgkin’s disease

HODGKIN’S DISEASE Staging • Stage I: single lymph node or contiguous group of nodes • Stage II: more than one node group, same side of diaphragm • Stage III: confined to nodes (and/or spleen) but present on both sides of diaphragm • Stage IV: spread outside nodes (liver, bone marrow, lung, etc) • Presence of symptoms (fever, weight loss, night sweats) designated by "B" after stage (no symptoms = "A") • Lower stage disease often treated with radiotherapy; higher stage disease with chemotherapy

HODGKIN’S DISEASE Response to treatment

Before treatment

After 6 months (Treatment completed)

After 7 years

MULTIPLE MYELOMA  Cancer of plasma cells (antibody-producing cells)  Most patients have monoclonal immunoglobulin (antibody-like protein) in blood or urine • This protein may damage kidneys, other organs  Bone destruction, bone marrow failure common

MULTIPLE MYELOMA

Red cells stuck together by abnormal protein (rouleaux)

Plasma cell

BONE LESIONS IN MYELOMA

View more...

Comments

Copyright � 2017 NANOPDF Inc.
SUPPORT NANOPDF